Form 4: Genelux Director Sells 10,000 Shares Under 10b5-1 Plan

Genelux Corporation Director Thomas John sold 10,000 shares of common stock for a weighted average price of $5.0008 per share on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Director Thomas John of Genelux Corporation (GNLX) reported a sale of common stock.
• The transaction involved 10,000 shares of common stock.
• The sale is scheduled to occur on December 1, 2025.
• The weighted average sale price for the transaction was $5.0008 per share, with prices ranging from $4.73 to $5.34.
• Following this transaction, Thomas John will beneficially own 492,784 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 4, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which typically has a neutral impact as it is not indicative of new information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent company developments.

Negatives

• A director, Thomas John, sold 10,000 shares of company common stock.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider sale as a slight negative, though mitigated by the pre-arranged 10b5-1 plan, which suggests the sale is not based on new, undisclosed information.

Key Dates

Recommendation

The filing details a pre-scheduled insider sale by a director, which is a routine event and does not provide new fundamental information about the company's performance or prospects. Therefore, it does not warrant a change in investment recommendation based solely on this transaction.

Keywords

Genelux Corporation, GNLX, Form 4, Insider Sale, Thomas John, Director, Stock Transaction, 10b5-1 Plan, Equity Sales